BEIJING, Aug 18 (Reuters): China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday (Aug 16).
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14 per cent in Monday's (Aug 17) morning session. Its Shanghai shares rose by 6.6 per cent as of midday. - Reuters
It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday (Aug 16).
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14 per cent in Monday's (Aug 17) morning session. Its Shanghai shares rose by 6.6 per cent as of midday. - Reuters
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
